

Complete Listing of the Claims:

1 – 79. (canceled)

80. (currently amended) A method of treating a clinical condition associated with increased activity of kallikrein, plasmin or Factor XIIa, ~~one or more serine proteases~~, comprising administering to a patient suffering from said clinical condition an effective amount of a pharmaceutical composition comprising the following polypeptide: ~~a polypeptide selected from at least one of the following sequences:~~

~~(DD103) EVVREVCSEQAETGPCRAMIFRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:130)~~
~~(DD104) EVVREVCSEQAETGPCRAMIYRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:131)~~
~~(DD105) EVVREVCSEQAETGPCRAMIWRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:132)~~
~~(TW6182) EVVREVCSEQAETGPCRAMIHRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:134)~~
~~(TW6194) EVVREVCSEQAETGPCRAMIERWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:135)~~
~~(DD185) EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:171)~~
~~(TW6165) EVVREVCSEQAETGPCRAAIWRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:172)~~
~~(TW6166) EVVREVCSEQAETGPCRAAIYRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:173)~~
~~(BG028) EVVREVCSEQAETGPCRALIYRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:174)~~
~~(TW6175) EVVREVCSEQAETGPCRALIFRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:177)~~
~~(TW6201) EVVREVCSEQAETGPCRAGIYRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:178)~~
~~(TW6202) EVVREVCSEQAETGPCRAGIWRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:179)~~
~~(DD114) EVVREVCSEQAETGPCRAAISRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:183)~~
~~(TW6183) EVVREVCSEQAETGPCRAMHFRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:185)~~
~~(TW6184) EVVREVCSEQAETGPCRAMHYRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:186)~~
~~(TW6185) EVVREVCSEQAETGPCRAMHWRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:187)~~
~~(BG003) EVVREVCSEQAETGPCRAMLHRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:188)~~
~~(TW6187) EVVREVCSEQAETGPCRAMIFRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:190)~~
~~(TW6188) EVVREVCSEQAETGPCRAMIYRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:191)~~
~~(TW6189) EVVREVCSEQAETGPCRAMIWRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:192)~~
~~(DD115) EVVREVCSEQAETGPCRGYITRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:194)~~
~~(TW6176) EVVREVCSEQAETGPCRAAHFRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:196)~~
~~(TW6177) EVVREVCSEQAETGPCRALHFRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:197)~~
~~(BG006) EVVREVCSEQAETGPCRAALFRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:198)~~
~~(DD130) EVVREVCSEQAETGPCRALFTRWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:199)~~
~~(BG014) EVVREVCSEQAETGPCRALIWHWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:204)~~
~~(DD122) EVVREVCSEQAETGPCRALIFAWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:205)~~
~~(BG015) EVVREVCSEQAETGPCRALIYHWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:206)~~
~~(BG020) EVVREVCSEQAETGPCRAAIHKWYFDVTEGKCAPFFYGGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:207)~~

(BG022)EVVREVCSEQAETGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEHCMVCGSAI (SEQ ID NO:208) .
(BG024)EVVREVCSEQAETGPCRALIYKWFYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:210)
(DD116)EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:212)
(TW6191)EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:213)
(BG029)EVVREVCSEQAETGPCRALIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:215)
(BG030)EVVREVCSEQAETGPCRALIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:216)
(BG033)EVVREVCSEQAETGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEHCMVCGSAI (SEQ ID NO:217)
(BG034)EVVREVCSEQAETGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:218)
(BG040)EVVREVCSEQAETGPCRALIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:219)
(BG025)EVVREVCSEQAETGPCRGLIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:223)
(BG026)EVVREVCSEQAETGPCRGAIIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:224)

81. (currently amended) A method for inhibiting activity of kallikrein, plasmin or Factor XIIa at least one serine protease in a mammal comprising administering a therapeutically effective dose of a pharmaceutical composition, together with a pharmaceutically acceptable sterile vehicle, wherein said composition comprises the following peptide: a polypeptide selected from at least one of the following sequences:

(DD103)EVVREVCSEQAETGPCRAMIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:130)
(DD104)EVVREVCSEQAETGPCRAMIYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:131)
(DD105)EVVREVCSEQAETGPCRAMIWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:132)
(TW6182)EVVREVCSEQAETGPCRAMIHRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:134)
(TW6194)EVVREVCSEQAETGPCRAMIERWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:135)
(DD185)EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:171)
(TW6165)EVVREVCSEQAETGPCRAAIWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:172)
(TW6166)EVVREVCSEQAETGPCRAAIYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:173)
(BG028)EVVREVCSEQAETGPCRALIYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:174)
(TW6175)EVVREVCSEQAETGPCRALIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:177)
(TW6201)EVVREVCSEQAETGPCRAGIYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:178)
(TW6202)EVVREVCSEQAETGPCRAGIWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:179)
(DD114)EVVREVCSEQAETGPCRAAISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:183)
(TW6183)EVVREVCSEQAETGPCRAMHFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:185)
(TW6184)EVVREVCSEQAETGPCRAMHYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:186)
(TW6185)EVVREVCSEQAETGPCRAMHWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:187)
(BG003)EVVREVCSEQAETGPCRAMLHRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:188)
(TW6187)EVVREVCSEQAETGPCRAMIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:190)
(TW6188)EVVREVCSEQAETGPCRAMIYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:191)
(TW6189)EVVREVCSEQAETGPCRAMIWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:192)
(DD115)EVVREVCSEQAETGPCRGYITRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMVCGSAI (SEQ ID NO:194)

(TW6176)EVVREVCSEQAETGPCRAAHFRWYFDVTEGKCAPFFYCGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:196)
(TW6177)EVVREVCSEQAETGPCRALHFRWYFDVTEGKCAPFFYCGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:197)
(BG006)EVVREVCSEQAETGPCRAALFRWYFDVTEGKCAPFFYCGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:198)
(DD130)EVVREVCSEQAETGPCRALFTRWYFDVTEGKCAPFFYCGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:199)
(BG014)EVVREVCSEQAETGPCRALIWHWYFDVTEGKCAPFFYCGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:204)
(DD122)EVVREVCSEQAETGPCRALIFAWYFDVTEGKCAPFFYCGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:205)
(BG015)EVVREVCSEQAETGPCRALIYHWYFDVTEGKCAPFFYCGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:206)
(BG020)EVVREVCSEQAETGPCRAAIHKWYFDVTEGKCAPFFYCGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:207)
(BG022)EVVREVCSEQAETGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEHCMVCGSAI (SEQ ID NO:208)
(BG024)EVVREVCSEQAETGPCRALIYKWYFDVTEGKCAPFFYCGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:210)
(DD116)EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCGRNRRNNFDTEEYCMVCGSAI (SEQ ID NO:212)
(TW6191)EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYCGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:213)
(BG029)EVVREVCSEQAETGPCRALIYHWYFDVTEGKCAPFFYCGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:215)
(BG030)EVVREVCSEQAETGPCRALIYHWYFDVTEGKCAPFFYCGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:216)
(BG033)EVVREVCSEQAETGPCRAAIYHWYFDVTEGKCAPFFYCGCCGNRNNFDTEEHCMVCGSAI (SEQ ID NO:217)
(BG034)EVVREVCSEQAETGPCRAAIYHWYFDVTEGKCAPFFYCGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:218)
(BG040)EVVREVCSEQAETGPCRALIYHWYFDVTEGKCAPFFYCGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:219)
(BG025)EVVREVCSEQAETGPCRGLIYHWYFDVTEGKCAPFFYCGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:223)
(BG026)EVVREVCSEQAETGPCRAIYHWYFDVTEGKCAPFFYCGCCGNRNNFDTEEYCMVCGSAI (SEQ ID NO:224)